Business
Resignation of CEO
SkinBioTherapeutics plc announced the resignation of its CEO, Stuart Ashman, following his suspension by the Board pending an investigation into his conduct. The Non-Executive Chairman, Martin Hunt, will temporarily assume the role of Executive Chairman, supported by the leadership team, while the company initiates a search for both an interim and a permanent CEO. The company stated it will provide further updates to the market in due course. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n \n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n \nResignation of CEO And Changes in Leadership Responsibilities\n \n13 February 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that CEO, Stuart Ashman, has resigned, having been suspended by the Board pending an investigation into matters relating to his conduct. The Company is undertaking a full investigation, supported by its professional advisors.\nMartin Hunt, Non-Executive Chairman, will assume the role and responsibilities of Executive Chairman temporarily; he will be supported by the rest of the Board and Leadership team to provide business leadership and continuity. The Company has instigated a search to find an interim CEO to appoint as soon as possible, and to find a new, permanent CEO for the longer term.\nThe Company will update the Market and shareholders in due course. Until then, there will be no further comment at this time.\n \nThis announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"MAR\"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\n \n-Ends-\nFor more information please contact:\n\n\n\n\nSkinBioTherapeutics plc Martin Hunt, Executive Chairman\nEmily Bertram, CFO\n\n\[email protected]\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\nJames Todd\nPatrick Weaver\n\n\n+44 (0) 020 7496 3000\n \n\n\n\n\nVigo Consulting Melanie Toyne-Sewell, Rozi Morris\n\n\n+44 (0) 20 7390 0230 [email protected]\n\n\n\n\n \n\n\n \n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where Ski...